COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities
In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical anal...
To prevent one hospitalisation over 6βmonths by boosting 31β207β42β836 students, a large university campus may also expect 1429.7β4625.9 young adults to experience grade β₯3 reactogenicity disrupting daily activities or requiring medical care when vaccinated with a third dose of BNT162b2 or mRNA-1273, respectively. Per million third-doses of mRNA vaccine administered, between 45β751.6 and 107 784.4 cases of grade β₯3 reactogenicity may be created
Per million third doses of mRNA vaccine administered, 23.3β32.0 hospitalisations may be averted while 47.6β147.0 cases of myo/pericarditis may be caused among young males aged 18β29 years (figure 1C). Thus, to prevent a single hospitalisation among young males aged 18β29 years, we estimate between 1.5 and 4.6 occurrences of myo/pericarditis (rates up to 1 in 700053) among males aged 18β29 years (figure 1C). For adolescents aged 16β17 years and using available data from CDCβs VSD,51 we expect 6.3 cases of myo/pericarditis among males and 1.4 among females. Thus, per single hospitalisation averted by boosting 31β207β42β836 young males in this age group, approximately 1.5β6.3 cases of myopericarditis may result.